Direct ISR target engagement likely requires trazodone doses around 150-200 mg/…

Mechanistic description

The most credible disease-modifying model is that trazodone must reach a higher exposure range, likely around 150-200 mg/day, to engage the PERK-eIF2alpha integrated stress response in neurons and restore translation. This remains a mechanistically grounded but unvalidated human threshold derived mainly from preclinical tauopathy/prion data and supported by the observation that many real-world dementia prescriptions were likely below this range.

Mechanism / pathway

EIF2AK3; EIF2S1; ATF4; DDIT3
→
neurodegeneration

Evidence for (4)

Trazodone rescued neurodegeneration and reversed eIF2alpha-P-linked translational repression in mouse prion and tauopathy models, with authors mapping efficacious exposure to a clinically relevant human dose estimate.

PMID:28430857
Follow-up proteomics showed trazodone rescued synaptic and mitochondrial nascent proteomes downstream of ISR dysregulation.

PMID:37703312
AD brains show activated UPR/ISR biology, supporting target relevance in human disease.

PMID:15973543
Phosphorylated eIF2alpha colocalizes with degenerating tau-positive neurons in AD.

PMID:12499843

Evidence against (3)

The proposed ~194 mg/day threshold is a mouse-to-human extrapolation, not a demonstrated human CNS target-engagement threshold.

PMID:28430857
Human clinical pharmacology at common doses is dominated by receptor occupancy and sedative effects, making mechanistic attribution uncertain.

PMID:29332554
Naturalistic dementia cohort data do not establish disease modification at any dose and were heavily confounded by low exposure and indication bias.

PMID:35921312

Evidence matrix

4 supporting 3 contradicting

57% supporting

Supporting

Trazodone rescued neurodegeneration and reversed eIF2alpha-P-linked translational repression in mouse prion and tauopathy models, with authors mapping efficacious exposure to a clinically relevant human dose estimate. PMID:28430857
Follow-up proteomics showed trazodone rescued synaptic and mitochondrial nascent proteomes downstream of ISR dysregulation. PMID:37703312
AD brains show activated UPR/ISR biology, supporting target relevance in human disease. PMID:15973543
Phosphorylated eIF2alpha colocalizes with degenerating tau-positive neurons in AD. PMID:12499843

Contradicting

The proposed ~194 mg/day threshold is a mouse-to-human extrapolation, not a demonstrated human CNS target-engagement threshold. PMID:28430857
Human clinical pharmacology at common doses is dominated by receptor occupancy and sedative effects, making mechanistic attribution uncertain. PMID:29332554
Naturalistic dementia cohort data do not establish disease modification at any dose and were heavily confounded by low exposure and indication bias. PMID:35921312

Cite this hypothesis

Citation

etl-backfill (2026). Direct ISR target engagement likely requires trazodone doses around 150-200 mg/…. SciDEX hypothesis. https://prism.scidex.ai/hypotheses/h-78a93db210

BibTeX

@misc{scidex_hypothesis_h78a93db,
  title        = {Direct ISR target engagement likely requires trazodone doses around 150-200 mg/…},
  author       = {etl-backfill},
  year         = {2026},
  howpublished = {SciDEX hypothesis},
  url          = {https://prism.scidex.ai/hypotheses/h-78a93db210},
  note         = {SciDEX artifact hypothesis:h-78a93db210}
}